Top Analyst Reports for AbbVie, RTX & IBM
View original at finance.yahoo.comTop Analyst Reports for AbbVie, RTX & IBM Tuesday, February 17, 2026 The Zacks Research Daily presents the best research output of our analyst team…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Improved mix, pricing discipline and operating leverage are enhancing EVI's earnings quality
80% confidenceRocky Mountain is working on margin-first execution which is driving structural recovery with manufacturing gross margin rising to 21.4% from 10%
80% confidenceEVI's earnings conversion remains pressured with net income dipping to $4.2 million as SG&A rose 26%, outpacing revenue growth
80% confidenceCheck Point is gaining from solid contributions of its growth-oriented products, primarily CloudGuard, Sandblast Zero-day threat prevention and Infinity solutions
80% confidenceBoise Cascade is hurting due to slow single-family housing starts, resulting in low volumes and unfavorable commodity pricing
80% confidenceSupply-chain challenges continue to affect the aerospace sector, which may adversely impact RTX
80% confidenceIBM's focus on quantum technology for solutions to complex problems beyond the reach of classical computing is a tailwind
80% confidenceStrength in hybrid cloud, AI-powered automation, and enterprise consulting is driving growth in IBM's Software and Consulting segment
80% confidenceAbbVie faces several headwinds like Humira LOE impact, slowing oncology sales and continued macro headwinds for Aesthetics
80% confidenceRocky Mountain faces near-term liquidity and covenant risk, with $0.6 million cash, continued operating losses, high-cost 12% debt and reliance on external funding
80% confidenceAbbVie delivered robust net sales growth in 2025 which is just the second full year following the Humira LOE in the United States
80% confidenceLATAM Airlines is focused on premium traffic and an efficient cost structure
80% confidenceIPG Photonics is benefiting from innovations such as the CROSSBOW laser counter-UAV system and growth in medical applications, particularly urology
80% confidenceEVI's fiscal 2025 acquisitions contributed $40 million in revenues and $2 million in net income year to date
80% confidenceIBM's acquisition spree has escalated integration risks, while its high debt level is burdensome
80% confidenceIBM is gaining traction on the Watsonx platform, which is likely to be its core technology platform for AI capabilities
80% confidenceDaVita's patient-centric care model leverages its platform and continued execution of targeted initiatives to improve treatment adherence is an added plus
80% confidenceAbbVie has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline that should drive long-term growth
80% confidenceRTX continues to receive ample orders for its wide range of combat-proven defense products from the Pentagon and its foreign allies
80% confidenceSteadily improving global commercial air traffic boosts RTX's sales
80% confidenceStrong service and parts growth support Penske's earnings, though declining BEV units and softer premium demand may limit near-term results
80% confidenceAbbVie's neuroscience portfolio is contributing to top-line growth
80% confidenceEasing demand momentum amid persistent headwinds hurts Shake Shack with limited traffic growth, inflation pressures and weather disruptions remaining a concern
80% confidenceAbbVie has successfully navigated Humira's loss of exclusivity by launching two other successful new immunology medicines, Skyrizi and Rinvoq
80% confidenceEVI delivered solid top-line momentum, with revenues rising 24% in the December quarter and 20% for the first six months of FY26, alongside gross margin expansion to ~31%
80% confidenceThe uncertainties created by the recent imposition of U.S. government-issued import tariffs pose a risk for RTX
80% confidenceEVI's operating cash flow improved to $5.1 million despite a $12.6 million inventory build
80% confidenceStrong volumes and a favorable mix across large commercial engines and Pratt Canada operations are expected to support RTX's growth momentum in the commercial aerospace market
80% confidenceSkyrizi and Rinvoq are performing extremely well, bolstered by approvals in new indications, and should support top-line growth in the next few years
80% confidenceRising expenses remain a concern for Affirm
80% confidence